Peptide Reference
Tesamorelin
Tesamorelin Acetate
A synthetic growth hormone releasing factor analog specifically FDA-approved for reducing excess abdominal fat in HIV-associated lipodystrophy.
Status
approved
Category
growth hormone
Typical cost
$600-1200/month (prescription)
Mechanism
Stimulates pulsatile release of growth hormone from the pituitary. More targeted toward visceral fat reduction than other GHRH analogs. Improves lipid profiles and reduces inflammatory markers.
Potential benefits
- Reduced visceral fat
- Improved lipid profile
- Better insulin sensitivity
- Preserved lean mass
- Enhanced quality of life
- Reduces visceral fat
- Improves body composition
- FDA-approved indication
- Preserves lean mass
Reported side effects
- Injection site reactions
- Joint pain
- Muscle aches
- Peripheral edema
- Increased blood sugar
- Hyperglycemia risk
Common dosing references
subcutaneous
2mg · Daily
3-6 months
Research notes
Tesamorelin in HIV lipodystrophy
2010
Demonstrated significant reduction in visceral adipose tissue compared to placebo
Tesamorelin FDA approval
2010
Significant visceral adipose tissue reduction in HIV patients
Regulatory and sourcing notes
FDA-approved (Egrifta) for HIV-associated lipodystrophy. Prescription required.
Prescription only. Specialty pharmacy distribution.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides